Salkind Gene 4
4 · Mobiquity Technologies, Inc. · Filed Dec 19, 2023
Insider Transaction Report
Form 4
Salkind Gene
Director10% Owner
Transactions
- Award
Common stock options
2023-12-19+100,000→ 7,715,931 totalExercise: $0.20From: 2023-12-19Exp: 2028-12-19→ Common Stock (100,000 underlying) - Disposition to Issuer
Preferred Stock Series H
2023-12-15+751,973→ 7,615,931 totalExercise: $0.20From: 2023-12-15→ Common Stock (7,519,730 underlying) - Award
Preferred Stock Series G
2023-12-15−300,789→ 3,103,990 totalExercise: $0.50From: 2023-11-07→ Common Stock (3,007,789 underlying)
Footnotes (2)
- [F1]Not applicable.
- [F2]The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.